More than a scaffold: Stromal modulation of tumor immunity

详细信息    查看全文

• 作者：Anna Johansson^a ; Juliana Hamzah^b ; Ruth Ganss^a ; ^{ganss@perkins.uwa.edu.au" class="auth_mail" title="E-mail the corresponding author}
• 关键词：CAFs ; cancer associated fibroblasts ; CTLA4 ; anti-cytotoxic T-lymphocyte-associated protein 4 ; CSF-1 ; colony stimulating factor-1 ; ECM ; extracellular matrix ; FAP ; fibroblast activation protein-α ; HEVs ; high endothelial venules ; IDO ; indoleamine-pyrrole 2 ; 3-dioxygenase ; LAG-3 ; lymphocyte activator gene-3 ; LER ; low-expressing region ; LFA-1 ; lymphocyte function antigen-1 ; LOX ; lysyl oxidase ; MIF ; macrophage migration inhibitor-1 ; NRP-1 ; neuropilin-1 ; NSCLC ; non-small cell lung cancer ; PD-1 ; programm
• 刊名：Biochimica et Biophysica Acta (BBA)-Reviews on Cancer
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：1865
• 期：1
• 页码：3-13
• 全文大小：1001 K

文摘

Current clinical success with anti-cancer immunotherapy provides exciting new treatment opportunities. While encouraging, more needs to be done to induce durable effects in a higher proportion of patients. Increasing anti-tumor effector T cell quantity or quality alone does not necessarily correlate with therapeutic outcome. Instead, the tumor microenvironment is a critical determinant of anti-cancer responsiveness to immunotherapy and can confer profound resistance. Yet, the tumor-promoting environment – due to its enormous plasticity – also delivers the best opportunities for adjuvant therapy aiming at recruiting, priming and sustaining anti-tumor cytotoxicity. While the tumor environment as an entity is increasingly well understood, current interventions are still broad and often systemic. In contrast, tumors grow in a highly compartmentalized environment which includes the vascular/perivascular niche, extracellular matrix components and in some tumors lymph node aggregates; all of these structures harbor and instruct subsets of immune cells. Targeting and re-programming specific compartments may provide better opportunities for adjuvant immunotherapy.